Citations

Clear

96 citation(s) found for "Sood, A".

Development and testing of an ex vivo, live tumor fragment platform for the prediction of immune checkpoint inhibitor response and relationship to approved biomarkers.
Braun, David A., Gierman, Hinco J., Sood, Chetan , Hrycyniak, Laura, Hernan, Hilary, Dana, Nicholas, Caenepeel, Sean, Vedder, Lindsey, Mukhopadhyay, Debabrata, Martin, Robert C. G., Broome, Barbara , Kokabi, Nima, Chen, Ruqin, Lou, Yanyan, Majeed, Umair, Ramos, Hilario J., Taube, Janis M., Petal, Premal, Advani, Pooja , Braun, David A. , Gierman, Hinco J. , Hrycyniak, Laura , Caenepeel, Sean , Sahni, Shalini, Mukhopadhyay, Debabrata , Martin, Robert C.G. , Kokabi, Nima , Majeed, Umair , Ramos, Hilario J. , Taube, Janis M

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 2646-2646

10.1200/jco.2026.44.16_suppl.2646 Get It

2646 Background: Immune checkpoint inhibitors (ICIs) have transformed the management of many advanced cancers but identifying patients who are likely or unlikely to benefit from ICI treatment remains a critical challenge. Biomarkers, such as PD-L1, mismatch repair deficiency, and tumor mutational burden, capture only static, unidimensional features of the complex tumor microenvironment, and therefore inadequately predict response to immunotherapy in patients. In contrast, live tumor fragments (LTFs) preserve the full complexity of the tumor microenvironment and enable functional ex vivo assessments of ICI activity. Previous efforts have had limited clinical applicability because they required larger resection specimens often collected at a single academic center. Here, the predictive capability of an ex vivo platform using core needle and forceps biopsies from multiple clinical sites was assessed and compared to approved biomarkers. Methods: Patients with eligible solid tumors (where ICI has an indication, including renal, non-small cell lung, bladder, colorectal, and triple-negative breast cancer, and others) were enrolled in ongoing, prospective observational trials (NCT05478538, NCT05520099, NCT06349642). Biopsies were cut into LTFs, encapsulated in hydrogel, and treated sequentially with IgG antibody followed by ICI (αPD-[L]1 with or without αCTLA-4). Cytokine production was assessed by a multiplexed bead-based immunoassay at multiple time points during ex vivo treatment. Using receiver operating characteristic and precision recall analyses, we identified 9 predictive cytokines (including IFN-γ, granzyme B, and CXCL9/10), which were used to develop the Elephas score (ELP-score) to assess cytokine response to ex vivo ICI treatment. Results: Of 167 eligible patient specimens, 85% (n = 142) passed quality control metrics and 130 were used for model development. Hierarchical clustering of cytokine production revealed that 27% (n = 35) of patient specimens exhibited a cytokine response to ICI. In a validation set of 20 tumors, collected from patients who were subsequently treated with ICI, ELP-score positivity correctly identified 9 of 11 patients (82%) who had an objective response (PR/CR) to ICI, including 2 patients who were negative for FDA-approved standard-of-care ICI biomarkers. Furthermore, 5 of 5 patients (100%) with clinical progressive disease were correctly characterized as ELP-score negative. Conclusions: Using routine biopsy specimens, the ex vivo live tumor platform accurately identifies patients with clinical response to ICI therapy, including those incorrectly identified by conventional biomarkers. Ongoing efforts will test these findings in an additional validation set. If confirmed, the ex vivo LTF platform could enable the identification of patients likely to benefit from ICI therapy. Clinical trial information: NCT05478538 , NCT05520099 , NCT06349642 .
Validity and Prognostic Value of the UCSD Dyspnea Questionnaire in Fibrotic Hypersensitivity Pneumonitis: A Multicenter Prospective Study
Swigris, Jeffrey J, Moua, Teng , Chaudhary, Sachin, Adams, Tracy N, Adegunsoye, Ayodeji, Scholand, Mary Beth , Sood, Namita , Vestal, Brian , Pérez, Evans R Fernández, Swigris, Jeffrey J. , Chaudhary, Sachin , Adegunsoye, Ayodeji , Pérez, Evans R. Fernández

Mayo Clinic

Annals of the American Thoracic Society | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag110 | PMID 42127979 Get It

Abstract Rationale Dyspnea is a prominent symptom of fibrotic hypersensitivity pneumonitis (fHP), limiting patients’ activity and impairing their quality of life. The University of California San Diego Shortness of Breath questionnaire (UCSD-SOBQ) is a 24-item instrument used to assess dyspnea severity in patients with various respiratory conditions. Objectives This study aimed to examine the reliability and responsiveness of the UCSD-SOBQ score, its validity as a measure of dyspnea severity, and its prognostic value in a prospective cohort with fHP. Methods We conducted psychometric analyses on UCSD-SOBQ response data and assessed the association between score changes and survival in patients with fHP who completed the UCSD-SOBQ and other HP severity metrics at baseline, 6 and 12 months. We introduce the reliable change index (RCI) and the likely change index (LCI) to assess the statistical significance of within-individual change in UCSD scores. Results At baseline, internal consistency was high (Cronbach’s alpha = 0.97). Significant moderately strong correlations were observed between UCSD-SOBQ scores and percent predicted forced vital capacity (FVC%), r = -0.46, percent predicted diffusing capacity of the lung for carbon monoxide (DLCO%), r = -0.32, and Borg dyspnea scores r = 0.56. UCSD-SOBQ scores were significantly different between the lowest and highest strata of FVC% (64.9 ± 18.9 vs. 36.2 ± 22.9), DLCO% and Borg scores. The threshold for worsening within-individual change in the UCSD-SOBQ score at 95% confidence was 12 points. A 1-point higher baseline UCSD-SOBQ score was associated with a 2% increase in the risk of death or transplant (HR 1.02, 95% CI 1.00, 1.04). Conclusions In fHP, the UCSD-SOBQ score is a reliable and valid measure of dyspnea severity, is responsive to change, discriminates patients with differing severities, and is associated with transplant free survival. Additional qualitative data and psychometric analyses could tailor the UCSD-SOBQ to fHP and may further improve its measurement properties.
Prognostic Impact of Quantitative CT Disease Extent and Pattern in Fibrotic Hypersensitivity Pneumonitis
Pérez, Evans R Fernández, Humphries, Stephen M, Lynch, David A, Moua, Teng , Chaudhary, Sachin, Adams, Traci N. , Adegunsoye, Ayodeji, Scholand, Mary Beth , Sood, Namita , Vestal, Brian , Pérez, Evans R. Fernández , Humphries, Stephen M. , Lynch, David A. , Chaudhary, Sachin , Adegunsoye, Ayodeji

Mayo Clinic

Annals of the American Thoracic Society | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag116 | PMID 42127984 Get It

Abstract Rationale Quantitative CT using multiple instance learning (MIL)-usual interstitial pneumonia (UIP) classifier and data-driven textural analysis (DTA) provides objective and reproducible measurements of disease pattern and extent, respectively. However, the understanding of their individual or combined relationships with outcomes in fibrotic hypersensitivity pneumonitis (fHP) remains limited. Objectives To determine whether visual CT patterns of fHP or UIP, a MIL-UIP classifier, baseline and changes in DTA over 12-months and DTA at 12 months are associated with progression-free survival (PFS) in fHP. Methods The primary cohort included 134 participants with fHP. Associations between CT variables and subsequent lung function change, and PFS were assessed using linear mixed models and Cox hazards models. Results were validated in a combined dataset from three independent populations (N = 216). Results Visual patterns of fHP or UIP were not associated with PFS. A baseline MIL-UIP classification and DTA were significantly associated with 24-month PFS. However, the MIL-UIP did not predict PFS after adjusting for DTA fibrosis extent. Over 12 months, a 1-point increase in DTA across and within patients resulted in a significant decline in FVC% and DLCO%. A 12-month change in DTA (HR = 1.07, 95%CI 1.01-1.13) and DTA at 12-months (HR = 1.03, 95%CI 1.01-1.05) were associated with subsequent 12-month PFS. Similar estimates were observed in the validation cohort. Conclusions In fHP, the objectively measured extent of lung fibrosis is more prognostic than either a UIP classifier or visual CT patterns of fHP or UIP. Baseline DTA, DTA at 12 months, and its change over 12-months are associated with PFS.
Abstract 1919: Longer leukocyte telomeres and specific alleles of telomere maintenance genes are independently associated with improved survival of colon cancer patients.
Garcia, Estela M. Cruz, Sarkar, Gobinda , Chen, Jun, Sood, Shubham , Kossick, Kim, Schupack, Daniel , Graham, Rondell, Druliner, Brooke, Heydari, Zahra , Helgeson, Lauren, Cawthon, Richard G., Boardman, Lisa A., Druliner, Brooke R. , Cawthon, Richard

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1919-1919

10.1158/1538-7445.am2026-1919 Get It

Abstract Background: Aberrations in telomere length have important implications in cancer development and progression. This study aimed to determine whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival outcomes. We also investigated whether genetic variants in telomere maintenance genes are associated with survival in these patients. Methods: Blood specimens were collected from 1,007 patients prior to receiving chemotherapy or radiation. Genomic DNA was extracted using the Promega Maxwell RSC instrument. LTL was measured in triplicate using monochrome multiplex PCR, where the average amplification value of telomeric repeats was termed T. Similarly, PCR amplification of a single-copy reference gene was performed, and its average amplification value was termed S. The telomere length for each sample was expressed as the T/S ratio. Genotyping of single-nucleotide polymorphisms (SNPs) in TERC, TERT, and OBFC1 genes was conducted at the institutional Genome Analysis Core facility. Kaplan-Meier survival curves were generated to evaluate patient survival outcomes. Results: Younger individuals (∼25 years) exhibited nearly a twofold longer LTL compared with older individuals (∼75 years). No significant difference in LTL was observed between stage II and stage III CRC patients. A strong inverse correlation was observed between patient age and LTL (Spearman’s r = -0.48; p = 1.13 × 10-58). Females had significantly longer LTL than males (p = 3.97 × 10-5). The TERC SNP rs1317082 was significantly associated with both overall survival (OS) and disease-free survival (DFS) in the combined stage II and stage III patient cohort (p = 0.017 and p = 0.023, respectively). Similarly, the OBFC1 SNP rs9419958 was significantly associated with OS (p = 0.016). Importantly, LTL itself was significantly associated with both OS and DFS (p = 0.008 and p = 0.044, respectively) among the combined stage II and stage III patients. Kaplan-Meier survival analyses demonstrated that age- and sex-adjusted LTL was predictive of long-term survival outcomes. Conclusions: Survival among patients with stage II and III colorectal cancer is significantly influenced by LTL. Additionally, specific allelic variants of telomere maintenance genes, including TERC and OBFC1, are independently associated with improved survival, irrespective of LTL. These findings suggest that peripheral blood LTL measurement, along with telomere-related genotyping, may serve as a valuable prognostic marker for colorectal cancer outcomes. Funding: Individualizing colorectal cancer patient care using the host and tumor telomere phenotype (RO1 CA204013), Curtiss Fund (92541775), C-SiG Core(s): Epigenomics & Spatial Biology Core, and Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567) Citation Format: Estela M. Cruz Garcia, Gobinda Sarkar, Jun Chen, Shubham Sood, Kim Kossick, Daniel Schupack, Rondell Graham, Brooke Druliner, Zahra Heydari, Lauren Helgeson, Richard G. Cawthon, Lisa A. Boardman. Longer leukocyte telomeres and specific alleles of telomere maintenance genes are independently associated with improved survival of colon cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1919.
Training for pediatric cannot intubate cannot oxygenate: surgical airway should replace needle cricothyrotomy
Lehman, Allison M.B., Amstutz, Paul, Moore, Jackson E. , Obersteadt, Christopher, Williams, Dominique, Waxman, Mary J., Blubaugh, Morgan , Parikh, Anaya, Walsh, Timothy R., Bruegger, Daniel E., Malik, Adrienne , Pirotte, Andrew, Johnson, Matthew D. , Obersteadt, Chris, Sood, Shawn , Pirotte, Andrew P.

Mayo Clinic

Frontiers in Disaster and Emergency Medicine | March 17, 2026 | Volume: 4 | Issue: No issue available | Pages: No page available

10.3389/femer.2026.1772381 | PMID 41928873 Get It

Failed pediatric endotracheal intubation, prompting surgical airway management via emergency front of neck access (eFONA), is an intrinsically challenging topic. While rare, all emergency airway providers must be equipped to handle these complex clinical scenarios, both through initial training and maintenance of competency. Needle cricothyrotomy is a commonly taught method in cannot intubate cannot oxygenate (CICO) scenarios for children under age eight. However, needle cricothyrotomy is technically difficult, profoundly rare, and maintaining competency is a challenge. From a multidisciplinary perspective, we examine the utility of continuing to teach needle cricothyrotomy and explore alternatives. This project group suggests that pediatric eFONA training across disciplines should focus on surgical tracheotomy rather than needle cricothyrotomy, with consideration given to specialty-specific human performance factors.
Case-Based Perspectives on the Management of Genitourinary Syndrome of Menopause
Cyriac, Jissy , Sood, Richa

Mayo Clinic

Clinics and Practice | March 12, 2026 | Volume: 16 | Issue: 3 | Pages: 60

10.3390/clinpract16030060 | PMID 41892504 Get It

Background and Objectives: Genitourinary syndrome of menopause (GSM), previously known as vulvovaginal atrophy, is a chronic, progressive hypoestrogenic condition affecting vulvovaginal, urinary and sexual health in women. Common symptoms include vaginal dryness, itching, dyspareunia, urinary urgency and recurrent urinary tract infections (UTIs). Despite the high prevalence, GSM is underdiagnosed and undertreated, thereby negatively impacting women’s quality of life. To illustrate the practical aspects of GSM diagnosis and provide evidence-based management, we present a case-based narrative review synthesizing recently published, high-quality evidence. Materials and Methods: Evidence was drawn from multiple sources through targeted searches of databases, and included the 2025 AUA/SUFU/AUGS guideline (AUA), the 2024 NICE network meta-analyses (NICE), a 2025 systematic review/meta-analysis in breast-cancer survivors, the 2020 Menopause Society GSM Position Statement, the 2018 NAMS/ISSWSH breast cancer consensus, several primary source citations and other high quality peer-reviewed publications. Results: Five illustrative composite case vignettes of GSM are presented to highlight the evaluation strategy and evidence-supported treatment choices. Nonhormonal options are the first line treatments for mild GSM symptoms, either with or without the addition of vaginal estrogen therapy. For moderate to severe GSM, low-dose vaginal estrogen, vaginal DHEA, and ospemifene are all effective FDA-approved options. In breast cancer survivors, individualized decisions with oncology input are warranted. Maximal caution and a shared decision-making approach is required for women using Aromatase Inhibitors (AIs) for breast cancer risk reduction when choosing treatments for GSM. Conclusions: Treating GSM improves vaginal, sexual and urinary outcomes and quality of life of women. Clinicians need to proactively screen for GSM and offer evidence-based treatment options. The treatment decisions in breast cancer survivors are nuanced, requiring a shared-decision approach.
Early to Mature, Early to Detect: Artificial Intelligence in the Risk Prediction and Diagnosis of Precocious Puberty
Chavan, Manisha, Tabassum, Sameena, Joshi, Divya Dinesh, Boppana, Kusalik , Banu, Nasreen, Kayarkar, Riya, Chauhan, Kalp, Yerrapragada, Gayathri, Elangovan, Poonguzhali, Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Agarwal, Shreshta, Wilson, Sancia Mary Jerold, Virmani, Mini , Ghosh, Atishya, Serwaah, Mimi Adu , Karuppiah, Shiva Sankari, Gopalakrishnan, Keerthy, Sood, Divyanshi, Rapolu, Swetha, Cherukuri, Swathi Priya , Arunachalam, S., Arunachalam, Shivaram P. , Elangovan, Poonguzhali , Elangovan, Poonguzhali , Arunachalam, S P , Natarajan, Thangeswaran , Shariff, Mohammad Naveed , Agarwal, Shreshta , Tabassum, Sameena , Banu, Nasreen, Yerrapragada, Gayathri

Mayo Clinic

Reproductive Medicine | February 13, 2026 | Volume: 7 | Issue: 1 | Pages: 9

10.3390/reprodmed7010009 Get It

Background/Objectives: Precocious puberty (PP), defined as the onset of secondary sexual characteristics before 8 years in girls and 9 years in boys, is associated with psychosocial distress, compromised adult height, and long-term metabolic risk. Early identification remains challenging, as current diagnostic approaches are largely reactive and rely on invasive or resource-intensive testing. This narrative review examines how artificial intelligence (AI) can support earlier risk prediction and detection of PP through integration of clinical, hormonal, imaging, lifestyle, and environmental data. Methods: A narrative literature review was conducted using PubMed, Scopus, Embase, Web of Science, and Google Scholar to identify relevant studies published between 2005 and 2025. Eligible studies included original research and high-quality reviews that examined AI-based approaches, such as machine learning and deep learning, in pediatric endocrinology, particularly for the prediction or diagnosis of central or peripheral precocious puberty. Studies incorporating clinical, hormonal, radiological, lifestyle, environmental, or multi-omics data relevant to AI modeling were included. Results: AI models, including XGBoost, random forest, convolutional neural networks, and regression-based approaches, have demonstrated potential utility in predicting central precocious puberty using hormonal, imaging, and growth data. Reported applications include automated bone age assessment, lifestyle and dietary risk stratification, and exploratory use of wearable-derived behavioral data. However, progress is limited by small pediatric datasets, population bias, limited interpretability, and unresolved ethical challenges related to privacy, consent, and equity. Conclusions: Artificial intelligence represents a promising decision-support approach for earlier, non-invasive, and individualized risk assessment in precocious puberty. Future progress will depend on the integration of longitudinal, multimodal data, the development of ethical models, and interdisciplinary collaboration among pediatric endocrinologists, data scientists, and public health stakeholders.
Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer
Sarkar, Gobinda , Chen, Jun, Sood, Shubham , Fischer, K., Kossick, Kim, Schupack, Daniel , Graham, Rondell, Druliner, Brooke, Heydari, Zahra , Helgeson, Lauren, Garcia, Estela Cruz, Cawthon, Richard , Boardman, Lisa, Graham, Rondell P. , Garcia, Edwin , Fischer, Karen, Graham, Rondell P , Cruz Garcia, Estela Mariel , Chen, Jun, Druliner, Brooke R. , Boardman, Lisa

Mayo Clinic

Cancers | February 2, 2026 | Volume: 18 | Issue: 3 | Pages: 490

10.3390/cancers18030490 | PMID 41681962 Get It

Background and aims: Aberrations in telomere length can have important implications in cancer. Using a cohort of 1007 patients, we investigated whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival. We also investigated whether some telomere maintenance genes are associated with survival in these patients. Methods: The Biobank for Gastrointestinal Health Research (BGHR), an ongoing project involving collection of biospecimens at the Mayo Clinic, was utilized to obtain data from patients diagnosed with stage II or III CRC. Blood samples were collected prior to chemotherapy/radiation and DNA was extracted for measuring median LTL. The main outcome measures were overall survival (OS) and disease-free survival (DFS) by disease stage. Results: A significant inverse relationship was observed with patient age and LTL (spearman correlation coefficient (r) = −0.48, 95%; p = 1.13 × 10−58). Females had significantly longer LTL than males (p = 3.97 × 10−5). The rs1317082 SNP in the TERC gene was significantly associated with both OS and DFS in combined stage II and stage III patients (p = 0.017 and p = 0.023, respectively). A statistically significant association of the OBFC1 SNP (rs9419958) was observed for OS for the combined stage II and stage III patients (p = 0.016). Importantly, LTL was significantly associated with both OS and DFS (p = 0.008 and 0.044 respectively) in combined stage II and stage III patients. Conclusions: Our results show that LTL is predictive of OS and DFS for stage II and III CRC patients, particularly over a longer follow-up, extending beyond five years after a diagnosis of CRC, and certain SNPs in genes involved in telomere maintenance are significantly associated with patient outcomes, independent of telomere length.
Blood Pressure Variability (BPV) as a Novel Digital Biomarker of Multisystem Risk and Diagnostic Insight: Measurement, Mechanisms, and Emerging Artificial Intelligence Methods
Pugalenthi, Lakshmi Sree , Senapati, Sidhartha Gautam , Gohri, Jay , Anam, Hema Latha, Madan, Hritik, Arora, Adi , Arora, Avni, LEE, JIEUN , Yerrapragada, Gayathri, Elangovan, Poonguzhali, Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Agarwal, Shreshta, Karuppiah, Shiva Sankari, Sood, Divyanshi, Rapolu, Swetha, Iyer, Vivek, Helgeson, Scott A. , Arunachalam, Shivaram P. , Iyer, Vivek , Elangovan, Poonguzhali , Elangovan, Poonguzhali , Natarajan, Thangeswaran , Agarwal, Shreshta , Iyer, Vivek N , Arunachalam, S P , Helgeson, Scott A , Shariff, Mohammad Naveed , Yerrapragada, Gayathri

Mayo Clinic

Biomedicines | January 30, 2026 | Volume: 14 | Issue: 2 | Pages: 317

10.3390/biomedicines14020317 | PMID 41751215 Get It

Hypertension has been traditionally known to be highlighted by mean blood pressure; however, emerging evidence exhibits that blood pressure variability (BPV), including short-term, day-to-day, and visit-to-visit fluctuations can have an implication across multiple body systems. Elevated BPV reflects repetitive hemodynamic stress, affecting the physiologic hemostasis contributing to vascular injury and end organ damage. This narrative review is a compilation of recent evidence on the prognostic value of BPV, explained by pathophysiology, various devices with its measurement approaches, and, essentially, the clinical implication of BPV and the use of such devices utilizing artificial intelligence. A comprehensive literature search across PubMed, Cochrane Library, Scopus, and Web of Science were conducted, focusing on observational studies, cohorts, randomized trials, and meta-analyses. Higher BPV has been associated with an increased risk of cardiovascular mortality, stroke, coronary events, and heart failure, the progression of chronic kidney disease, cognitive decline, and preeclampsia, among other end organ damage, despite mean blood pressure. The various pathophysiologic mechanisms include autonomic dysregulation, arterial stiffness, endothelial dysfunction, circadian rhythm alteration, and systemic inflammation, which result in vascular remodeling and multisystem damage. Antihypertensive medications such as calcium channel blockers and renin–angiotensin–aldosterone system inhibitors seem to reduce BPV; randomized trials have not specifically investigated their BPV-reducing effects. The aim of this review is to highlight that BPV is a dynamic marker of multisystem risk, and question how various AI-based devices can aid continuous BPV monitoring and patient specific risk stratification.
Prospective of Colorectal Cancer Screening, Diagnosis, and Treatment Management Using Bowel Sounds Leveraging Artificial Intelligence
Sood, Divyanshi, Dadwal, Surbhi, Jain, Samiksha , Mazhar, Iqra, Goyal, Bipasha, Garapati, Chris Alex Wesley, Patel, Sagar , RIAZ, ZENAB MUHAMMAD, Buzaboon, Noor, Mendiratta, Ayushi, Kaur, Avneet , Yerrapragada, Gayathri, Elangovan, Poonguzhali, Shariff, Mohammed Naveed , Natarajan, T.K. , Janarthanan, Jayarajasekaran, Agarwal, Shreshta, Wilson, Sancia Mary Jerold, Ghosh, Atishya, Karuppiah, Shiva Sankari, Agarwal, Joshika, Gopalakrishnan, Keerthy, Rapolu, Swetha, Akshintala, Venkata S. , Arunachalam, Shivaram P. , Elangovan, Poonguzhali , Mazhar, Iqra Jabeen , Garapati, Chris, Elangovan, Poonguzhali , Shariff, Mohammad Naveed , Natarajan, Thangeswaran , Agarwal, Shreshta , Jerold Wilson, Sancia Mary, Akshintala, Venkata , Arunachalam, S P , Dadwal, Surbhi , Mendiratta, Ayushi, Mohan, Anmol , Yerrapragada, Gayathri

Mayo Clinic

Cancers | January 21, 2026 | Volume: 18 | Issue: 2 | Pages: 340

10.3390/cancers18020340 | PMID 41595259 Get It

Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide, accounting for approximately 10% of all cancer cases. Despite the proven effectiveness of conventional screening modalities such as colonoscopy and fecal immunochemical testing (FIT), their invasive nature, high cost, and limited patient compliance hinder widespread adoption. Recent advancements in artificial intelligence (AI) and bowel sound-based signal processing have enabled non-invasive approaches for gastrointestinal diagnostics. Among these, bowel sound analysis—historically considered subjective—has reemerged as a promising biomarker using digital auscultation and machine learning. Objective: This review explores the potential of AI-powered bowel sound analytics for early detection, screening, and characterization of colorectal cancer. It aims to assess current methodologies, summarize reported performance metrics, and highlight translational opportunities and challenges in clinical implementation. Methods: A narrative review was conducted across PubMed, Scopus, Embase, and Cochrane databases using the terms colorectal cancer, bowel sounds, phonoenterography, artificial intelligence, and non-invasive diagnosis. Eligible studies involving human bowel sound-based recordings, AI-based sound analysis, or machine learning applications in gastrointestinal pathology were reviewed for study design, signal acquisition methods, AI model architecture, and diagnostic accuracy. Results: Across studies using convolutional neural networks (CNNs), gradient boosting, and transformer-based models, reported diagnostic accuracies ranged from 88% to 96%. Area under the curve (AUC) values were ≥0.83, with F1 scores between 0.71 and 0.85 for bowel sound classification. In CRC-specific frameworks such as BowelRCNN, AI models successfully differentiate abnormal bowel sound intervals and spectral patterns associated with tumor-related motility disturbances and partial obstruction. Distinct bowel sound-based signatures—such as prolonged sound-to-sound intervals and high-pitched “tinkling” proximal to lesions—demonstrate the physiological basis for CRC detection through bowel sound-based biomarkers. Conclusions: AI-driven bowel sound analysis represents an emerging, exploratory research direction rather than a validated colorectal cancer screening modality. While early studies demonstrate physiological plausibility and technical feasibility, no large-scale, CRC-specific validation studies currently establish sensitivity, specificity, PPV, or NPV for cancer detection. Accordingly, bowel sound analytics should be viewed as hypothesis-generating and potentially complementary to established screening tools, rather than a near-term alternative to validated modalities such as FIT, multitarget stool DNA testing, or colonoscopy.